Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1996 1
2000 1
2001 4
2002 1
2006 1
2008 1
2009 2
2011 2
2012 4
2013 6
2014 8
2015 5
2016 6
2017 3
2018 4
2019 3
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Among authors: srimuninnimit v. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.
de Castro G Jr, Kudaba I, Wu YL, Lopes G, Kowalski DM, Turna HZ, Caglevic C, Zhang L, Karaszewska B, Laktionov KK, Srimuninnimit V, Bondarenko I, Kubota K, Mukherjee R, Lin J, Souza F, Mok TSK, Cho BC. de Castro G Jr, et al. Among authors: srimuninnimit v. J Clin Oncol. 2023 Apr 10;41(11):1986-1991. doi: 10.1200/JCO.21.02885. Epub 2022 Oct 28. J Clin Oncol. 2023. PMID: 36306479 Free PMC article. Clinical Trial.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Gianni L, et al. Among authors: srimuninnimit v. Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6. Lancet Oncol. 2012. PMID: 22153890 Clinical Trial.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P. Gianni L, et al. Among authors: srimuninnimit v. Lancet Oncol. 2016 Jun;17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7. Epub 2016 May 11. Lancet Oncol. 2016. PMID: 27179402 Clinical Trial.
The first Smartphone application for microsurgery monitoring: SilpaRamanitor.
Kiranantawat K, Sitpahul N, Taeprasartsit P, Constantinides J, Kruavit A, Srimuninnimit V, Punyahotra N, Chatdokmaiprai C, Numhom S. Kiranantawat K, et al. Among authors: srimuninnimit v. Plast Reconstr Surg. 2014 Jul;134(1):130-139. doi: 10.1097/PRS.0000000000000276. Plast Reconstr Surg. 2014. PMID: 25028822
Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer.
Srimuninnimit V, Pornpraserthsuk P, Chaiwerawattana A, Kongdan Y, Namkanisorn T, Somwangprasert A, Jatuparisuthi C, Puttawibul P, Vongsaisuwan M, Thongthieang L, Bandidwattanawong C, Tantimongkolsuk C. Srimuninnimit V, et al. PLoS One. 2018 Dec 19;13(12):e0209040. doi: 10.1371/journal.pone.0209040. eCollection 2018. PLoS One. 2018. PMID: 30566471 Free PMC article.
Cost-Utility and Budget Impact Analyses of Oral Chemotherapy for Stage III Colorectal Cancer: Real-World Evidence after Policy Implementation in Thailand.
Phisalprapa P, Kositamongkol C, Korphaisarn K, Akewanlop C, Srimuninnimit V, Supakankunti S, Apiraksattayakul N, Chaiyakunapruk N. Phisalprapa P, et al. Among authors: srimuninnimit v. Cancers (Basel). 2023 Oct 11;15(20):4930. doi: 10.3390/cancers15204930. Cancers (Basel). 2023. PMID: 37894297 Free PMC article.
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
Riechelmann RP, Srimuninnimit V, Bordonaro R, Kavan P, Di Bartolomeo M, Maiello E, Cicin I, García-Alfonso P, Chau I, Fedyanin MY, Martos CF, Ter-Ovanesov M, Peeters M, Ko YJ, Yalcin S, Karthaus M, Aparicio J, Heinemann V, Picard P, Bury D, Drea E, Sobrero A. Riechelmann RP, et al. Among authors: srimuninnimit v. Clin Colorectal Cancer. 2019 Sep;18(3):183-191.e3. doi: 10.1016/j.clcc.2019.05.003. Epub 2019 May 15. Clin Colorectal Cancer. 2019. PMID: 31221542 Free article. Clinical Trial.
48 results